8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Sep 8, 2021)

Filed September 8, 2021For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report detailing the departure of Laurie B. Keating, Executive Vice President, Chief Legal Officer, and Secretary, effective September 10, 2021, after seven years of service. This executive transition involves a consulting agreement with Ms. Keating for an 18-month period, during which she will provide up to 10 hours of consulting services per month. In exchange for her continued support and a release of claims, Ms. Keating will receive a comprehensive compensation package including 12 months of her current base salary, a pro-rata 2021 bonus based on performance, and 12 months of health coverage premium contributions. Importantly, her existing equity awards will continue to vest and remain exercisable during her consultancy, aligning her interests with the Company's performance. Investors should note this is an operational transition rather than a negative event, with the company securing valuable expertise during the handover period.

Key Highlights

  • 1Laurie B. Keating, EVP, Chief Legal Officer & Secretary, is retiring and resigning effective September 10, 2021.
  • 2Ms. Keating will provide consulting services to Alnylam for up to 10 hours per month for an 18-month period.
  • 3She will receive 12 months of her current base salary in cash compensation.
  • 4A pro-rata cash bonus for 2021, based on actual performance, will be paid.
  • 5The company will contribute to her health coverage premiums for 12 months post-employment.
  • 6Ms. Keating's equity awards will continue to vest and remain exercisable during her consultancy.
  • 7The agreement includes a release of claims and standard terms and conditions.

Frequently Asked Questions

This 8-K filing is primarily to report the retirement and resignation of Laurie B. Keating, a key executive officer (EVP, Chief Legal Officer, and Secretary), and to detail the terms of her subsequent consulting agreement and compensation.

The financial impact involves continued compensation for Ms. Keating, including 12 months of base salary, a pro-rata bonus, and health premium contributions. While this represents an ongoing expense, it ensures continuity and access to her expertise. The continuation of equity vesting also aligns her incentives with company performance.

While Ms. Keating is stepping down from her officer roles, the company has arranged for her to provide consulting services for 18 months. This transition plan aims to maintain stability and leverage her knowledge during the handover period. The company will need to appoint a successor for her officer positions.

The consulting agreement allows Alnylam to retain Ms. Keating's institutional knowledge and expertise for an extended period, ensuring a smoother transition for her successor and ongoing support on legal matters. The continuation of equity vesting further incentivizes her continued engagement and alignment with shareholder value.